<DOC>
	<DOC>NCT01450488</DOC>
	<brief_summary>The purpose of this study is to evaluate the activity of oral AB1010, administered at two dose levels during 3 years to patients with primary or secondary progressive multiple sclerosis.</brief_summary>
	<brief_title>Masitinib in Patients With Primary Progressive Multiple Sclerosis (PPMS) or Relapse-free Secondary Progressive Multiple Sclerosis (SPMS)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
	<criteria>1. Patients aged 18 to 60 years, from both sex, and suffering from multiple sclerosis either primary progressive or secondary progressive without relapse within 2 years before inclusion. 2. Patients with EDSS score in the range of 2 to 6.5, inclusive 3. EDSS progression â‰¥ 1 point within 2 years before inclusion 1. Disease other than MS responsible for clinical signs and/or MRI lesions 2. Secondary progressive MS with relapse in the 2 years before inclusion 3. Treatment with interferon or glatiramer acetate within four weeks prior to treatment allocation 4. Treatment with oral or systemic corticosteroids or ACTH within four weeks prior to treatment allocation. 5. Active current bacterial, viral (including hepatitis B and C, HIV, EBV, CMV, herpes zoster, herpes simplex), fungal, mycobacterium, protozoan, or other infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>primary progressive multiple sclerosis</keyword>
	<keyword>relapse-free secondary progressive multiple sclerosis</keyword>
</DOC>